SPOTLIGHT -
Slideshow
Author(s):
Some speculate the pharmaceutical industry has virtually abandoned new drug development in neuroscience with a few exceptions. However, it should be noted that progress has been made.
The Double-Edged Sword of Affluence
Blue Light Blockers: A Behavior Therapy for Mania
FDA Filing Fee Waiver for New Drug Application of NRX-100 for Suicidal Depression
Blue Light, Depression, and Bipolar Disorder
Depression, Apathy, and Anxiety in Parkinson Disease
Transneural Therapeutics: A New Company to Develop Novel Neuroplastogens